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The function of the secretory core gene product (HBeAg) of the human hepatitis B virus (HBV) is unknown. It has been
proposed that this protein may be passed from the mother to her offspring at the perinatal stage where it might induce
immune tolerance. In a previous study we have shown that the murine placenta presents an efficient barrier for the HBe
protein and that H-2b mice born to HBeAg-positive transgenic mothers do not develop tolerance of specific cytotoxic T cells.
In the present work we demonstrate that transgenic mice expressing high serum levels of HBeAg secrete only small amounts
of this protein into their milk and excrete minute amounts of the viral gene product in their urine. Furthermore, it is shown
that nontransgenic H-2d mice born to and reared by HBeAg-positive mothers exhibit a reactivity of HBc/eAg-specific CD41
Th cells and CD81 cytotoxic T cells comparable to that of normal isogenic control mice. In accordance with this observation
the humoral immune responses directed against the HBeAg were comparable between these two groups of animals. This
finding indicates that H-2d mice potentially exposed to small amounts of maternal HBeAg transferred by the transplacental,
lactogenic, or renal route do not develop tolerance toward the HBV core gene products. These data challenge the hypothesis











The human hepatitis B virus (HBV) causes acute and
chronic liver disease and hepatocellular carcinomas.
Whereas infected newborn individuals almost invariably
become chronic virus carriers, only a small fraction of the
infections of adults enter a chronic disease course. It has
been speculated that the high rate of chronicity observed
after viral infection of juvenile persons may result from a
tolerogenic action of certain viral gene products. One
viral protein suspected to promote chronicity of viral
disease is the HBe antigen (HBeAg), which is encoded
by the core gene (Ganem and Varmus, 1987; Garcia et al.,
1988; Junker et al., 1987; Ou et al., 1986; Schlicht et al.,
987). The coding capacity of this gene is expanded by
ifferential usage of two in-frame translational start
odons, encompassing a small open reading frame
ORF) designated preC-ORF. Initiation of core gene tran-
cription within the preC region gives rise to pregenomic
NA, which, in addition to other essential functions,
ncodes the core protein or HBc antigen (HBcAg). How-
ver, core gene transcription can also initiate upstream
rom the preC-region, which results in the synthesis of a
econd mRNA species designated precore mRNA. The
recore transcript gives rise to a precursor protein that,
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: 0049-6131-3930220. E-mail: reifenbe@mail.uni-mainz.de.
149ue to the action of a preC-encoded signal sequence, is
ranslocated into the lumen of the endoplasmic reticu-
um. Upon N- and C-terminal proteolytic cleavage the
recursor is converted into the mature HBeAg, which is
fficiently secreted into the serum of HBV-infected per-
ons. Although it has been demonstrated in a multitude
f studies that the secretory core gene product is not
ecessary for viral replication (Chang et al., 1987;
chlicht et al., 1987; Chen et al., 1992; Ogata et al., 1993),
all of the hepadnaviruses known to date encode such a
viral product.
HBeAg-transgenic mice represent an important model
for investigating the tolerogenic potential of the HBV
secretory core gene product. In a previous study it was
demonstrated that nontransgenic H-2s mice born to and
reared by HBeAg-expressing transgenic females show a
weak yet significant tolerance of CD41 Th cells specific
for HBV core gene products (Milich et al., 1990). Although
the experimental design of this study did not allow one to
discriminate whether the immune tolerance observed
resulted from a prenatal HBeAg exposition or was due to
a postnatal mechanism of tolerance induction, it was
concluded that the HBe protein can pass the placenta
and induce immune tolerance in utero. In this study, the
extent to which the Th cell tolerance observed may
potentially affect specific antibody synthesis was not
investigated. In this context it is important to mention that
core-specific Th cells not only promote the biosynthesis
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150 MERKLE ET AL.of HBeAg-specific antibodies but by using a mechanism
referred to as intramolecular help (Milich et al., 1987a)
also have the potential to support the synthesis of HBs-
Ag-specific antibodies. Although it is controversial
whether the emergence of antibodies directed against
the HBeAg may contribute to viral clearance (Schlicht
and Schaller, 1989) or merely represents an immunolog-
ically irrelevant epiphenomenon (Merkle et al., 2000), the
protective properties of anti-HBs antibodies are well doc-
umented. Recently, we have demonstrated that the mu-
rine placenta presents an efficient barrier for the HBeAg
(Reifenberg et al., 1998), strongly challenging the hypoth-
sis that the HBe protein has the potential to induce
mmune tolerance at the prenatal stage. In accordance
ith these results we found no evidence that H-2b mice
born to and reared by HBeAg-transgenic mothers de-
velop tolerance of HBc/eAg-specific cytotoxic T cells
(CTLs; Reifenberg et al., 1998).
The aim of the present study was to clarify the con-
tradictory results observed in the two experimental stud-
ies mentioned above (Milich et al., 1990; Reifenberg et
al., 1998) using HBeAg-transgenic mice. To this end we
further analyzed the routes by which the HBe protein may
be transferred from HBeAg-transgenic mothers to their
nontransgenic offspring. To investigate whether the peri-
natal contact with small amounts of maternal HBeAg
transferred by the transplacental, lactogenic, or renal
route may induce specific immune tolerance we ana-
lyzed the T cell reactivity of nontransgenic mice born to
and reared by HBeAg-positive transgenic mothers. Pre-
vious experimental studies investigating the potential of
maternal HBeAg to tolerize mice were performed in the
H-2s or H-2b haplotype system (Milich et al., 1990; Reif-
nberg et al., 1998), neither of which allows for the
nalysis of all types of HBeAg-specific immunocytes.
hus, all attempts have failed to elicit murine HBc/eAg-
pecific CTL immune reactions in mice of the H-2s hap-
lotype (Townsend et al., 1997), excluding the possibility of
analyzing HBeAg-induced CTL tolerance effects in such
animals. On the other hand, the immunodominant HBc/
eAg determinant recognized by H-2b-restricted CD41
cells is immunogenic, yet not tolerogenic (Milich et al.,
1989), preventing analysis of core-specific Th cells in
H-2b mice. Therefore, the present study was conducted
n BALB/c mice that exhibit the H-2d haplotype. This
murine haplotype allows for induction of both HBc/Ag-
specific Th reactions and CTL immune responses and
thus overcomes the restrictions associated with the us-
age of H-2s or H-2b mice. Furthermore, the immunodom-
inant epitopes recognized by specific H-2d-restricted Th
and CTL cells have been mapped (Milich et al., 1987b;
Kuhrober et al., 1997).
We found that transgenic mice displaying high HBeAg
serum titers secrete only small amounts of the trans-
genic protein into their milk and excrete minor quantities
of the viral antigen in their urine. BALB/c mice (haplotype
f
iH-2d) born to HBeAg-transgenic mothers showed a com-
arable reactivity of HBc/eAg-specific Th cells and CTLs
s normal controls. In line with this observation the
umoral immune responses directed against the HBeAg
ere similar between these two groups of mice. In con-
rast, HBeAg-transgenic BALB/c mice showed a toler-
nce at the level of core-specific Th cells and CTLs. This
ndicates that mice of the H-2d haplotype potentially
xposed to small amounts of maternal HBeAg at the
erinatal stage do not develop significant tolerance to-
ard the HBV core gene products. These data challenge
he hypothesis that a potential function of the HBeAg
ay be to operate as a tolerogen at the perinatal stage.
RESULTS
ALB/c–cex-1 transgenic females secrete small
mounts of HBeAg into their milk and excrete minor
uantities of the viral protein into their urine
Milk and urine samples of BALB/c–cex-1 transgenic
ice were collected at day 10 of lactation and the HBeAg
oncentrations were determined. As depicted in Fig. 1,
he lactating females displayed high HBeAg serum titers
51.8 ng/ml) at the time of milk and urine collection,
ndicating that the transgene was well expressed. How-
ver, the mean concentrations of HBeAg detectable in
he maternal milk and urine samples were 3.1 and 0.1
g/ml, respectively.
In our subsequent experiments we investigated
hether low-level galactogenic and renal HBeAg trans-
er as well as HBe antigen potentially passing the murine
lacenta in amounts escaping enzymatic detection (Rei-
FIG. 1. BALB/c–cex-1 transgenic females secrete small amounts of
HBeAg into their milk and excrete minor quantities of the viral protein
into their urine. Serum, urine, and milk samples were prepared from
BALB/c–cex-1 transgenic females at day 10 of lactation and analyzed
for HBeAg. Note that the viral protein is well expressed in the serum of
the lactating mice (51.8 ng/ml). Small quantities of HBe antigen (3.1
ng/ml) are secreted lactogenically, whereas only minor amounts of the
































































151HBe TOLERANCE INDUCTIONEvaluation of the reactivity of HBV core-specific H-2d-
restricted CD41 Th cells
Previously, the immunodominant H-2d-restricted Th
ell epitope shared by the two HBV core gene products
as mapped to HBc/eAg amino acids 85–100 (Milich et
al., 1987b). To establish a suitable assay system for the
valuation of the reactivity of specific CD41 H-2d T helper
ells we synthesized a peptide encompassing HBc/eAg
mino acids 85–100 (referred to as p85–100) and used it
o immunize H-2d BALB/c mice. The same peptide was
also used to restimulate the primed splenocytes in vitro.
To control for the specificity of the immune reaction
elicited, the cultured cells were additionally restimulated
with HBc/eAg peptide p129–140, representing the immu-
nodominant determinant recognized by H-2b-restricted
BV core-specific T cells (Milich et al., 1989). Prolifera-
ive responses were determined as described under
aterials and Methods. As depicted in Fig. 2A the
rimed splenocytes showed vigorous dose-dependent
roliferation upon stimulation with peptide p85–100 but
ailed to respond to the nonspecific peptide p129–140,
ndicating that HBc/eAg peptide p85–100 is well suited to
nduce T cell proliferative responses in H-2d mice. How-
ever, HBc/eAg peptide p85–100 completely overlaps with
the amino acid region previously found to represent the
immunodominant CTL epitope (HBc/eAg amino acids
87–95) recognized by H-2d-restricted CD81 core-specific
cells (Kuhrober et al., 1997). Hence, the possibility that
he T cell responses elicited were due to proliferative
eactions of CD81 CTLs could not be excluded. To clarify
his point, splenocytes obtained from p85–100-treated
-2d mice either were depleted of CD41 cells or were left
ndepleted prior to restimulation. As shown in Fig. 2B,
he undepleted control cells showed a vigorous prolifer-
tive response toward peptide p85–100, whereas the
roliferation levels of the CD4-depleted cell population
ere significantly impaired, indicating that the T cell
roliferation assay established almost exclusively re-
lected the reactivity of CD41 Th cells.
CD41 Th cells prepared from H-2d mice born to and
eared by HBeAg-transgenic mothers are not tolerant
oward the core gene products
To verify the data of Milich and co-workers (Milich et
l., 1990) in the H-2d haplotype system, BALB/c males
ere mated with hemizygous BALB/c-cex-1 transgenic
emales and the babies were reared by their HBeAg-
xpressing mothers. To control for efficient transgene
xpression, the HBeAg serum titers of the transgenic
others were determined at the onset of sexual maturity
nd at the end of their reproductive life span. We found
hat the HBeAg levels were approximately 40 ng/ml and
hat the titers varied by no more than about 20% (data not
hown). Nontransgenic offspring of transgenic mothers
ere identified by PCR analysis of genomic DNA. As
p
iontrols we used normal BALB/c mice and transgenic
ALB/c–cex-1 mice constitutively expressing the HBe
rotein in the serum. Since in previous studies it had
een demonstrated that tolerance of murine H-2s-re-
tricted HBc/eAg-specific Th cells induced by a single
BcAg injection into newborn mice persisted up to an
ge of 3 months (Milich et al., 1990), immunizations were
erformed at an age of 40–60 days. Animals of the three
xperimental groups mentioned were treated with pep-
ide p85–100 and their splenocytes were restimulated
ith peptide p85–100 or the negative control peptide
FIG. 2. Immunization with HBc/eAg peptide p85–100 elicits a vigor-
ous proliferation of H-2d-restricted CD41 T cells. BALB/c (H-2d) mice
ere immunized with HBc/eAg peptide p85–100 representing the im-
unodominant epitope recognized by core-specific H-2d-restricted
CD41 cells. The mice were sacrificed 12 days postimmunization and
cultured splenocytes were restimulated with various concentrations of
HBc/eAg peptides. The proliferative responses induced were evaluated
by [3H]thymidine uptake. The proliferation levels of individual animals
ere assessed in triplicate and corrected for background radiation
Dcpm). In experiment A the primed splenocytes were restimulated
ith peptide p85–100 (values in squares) or the negative control pep-
ide p129–140 (values in triangles). Note that the cells showed a
ose-dependent proliferative response upon restimulation with HBc/
Ag peptide p85–100 but failed to respond to the negative control
eptide p129–140, indicating the specificity of the immune reaction. In
xperiment B the splenocytes harvested from p85–100 immunized
ALB/c mice either were depleted of CD41 cells (values in rhombuses)
or were left undepleted (values in circles) prior to p85–100 restimula-
tion. Note that the undepleted cells showed a vigorous proliferative
response, whereas the proliferation levels of the depleted cell popula-
tion were significantly impaired, indicating that the proliferation assay
established almost exclusively indicated the reactivity of CD41 cells.
he data shown represent mean values of two mice each.129–140. As expected, the normal BALB/c mice exhib-





















152 MERKLE ET AL.trast, the proliferation levels of transgenic BALB/c–cex-1
splenocytes (Fig. 3A) were impaired significantly (T test).
mportantly, the spleen cell proliferative responses of
ALB/c mice born to and reared by HBeAg transgenic
others (Fig. 3C) were comparable to those of the
ALB/c controls.
Since it is well established that the humoral immune
esponses directed against the secretory core gene
roduct strictly depend on the help of CD41 cells (Milich
et al., 1988), it was of interest to determine the potential
of BALB/c mice born to HBeAg-transgenic mothers to
synthesize HBeAg-specific antibodies. To this end, mice
of the three experimental groups mentioned were immu-
nized with the HBeAg-encoding plasmid pGW-I1. Serum
samples were prepared from the immunized animals at
months 0, 1, 2, 3, and 4 postimmunization and analyzed
for specific antibodies. Sera of transgenic mice were
additionally monitored for HBeAg expression. The nor-
mal BALB/c controls showed a vigorous biosynthesis of
HBe-specific antibodies (Fig. 4B), whereas no such an-
tibodies could be detected in the sera of the transgenic
FIG. 3. H-2d BALB/c mice born to and reared by HBeAg-transgenic
ransgenic BALB/c–cex-1 mice (A), normal BALB/c controls (B), and
mmunized with HBc/eAg peptide p85–100 representing the immunodo
ge of 40 to 60 days. The mice were sacrificed 12 days postimmunizati
ith various concentrations of peptide p85–100 or the negative control p
ptake. The proliferation levels of individual animals were assessed by
ata shown represent mean values plus standard deviation of eight mic
olerance as determined by their p85–100 proliferation levels. In co
BeAg-transgenic mothers (C) were similar to those of the normal i
roliferate upon restimulation with control peptide p129–140.controls (Fig. 4A). In accordance with the deficit of trans-
genic mice to synthesize anti-HBe, the HBeAg serum
Htiters of such animals were not affected by DNA immu-
nization (data not shown). In this context it is important to
mention that it was not a problem to elicit anti-HBc
antibodies in the transgenic mice (data not shown), in-
dicating that these animals were not tolerant at the B cell
level. Hence, the absent HBe-specific humoral reactions
of the transgenic animals were most probably due to
their Th cell tolerance. Importantly, the HBe-specific an-
tibody responses of BALB/c mice born to and reared by
HBeAg-positive mothers (Fig. 4C) were not significantly
reduced in comparison to those of the isogenic normal
controls (T test).
H-2bxs mice born to HBeAg-positive mothers exhibit a
ormal HBe-specific humoral immune response
It was of interest to investigate whether the slight Th
ell tolerance previously observed in B10.S (H-2s) mice
orn to HBeAg transgenic mothers (Milich et al., 1990)
ight reflect on the level of antibody biosynthesis. These
tudies were conducted in H-2bxs hybrid mice, coex-
pressing the H-2b and H-2s haplotypes. Nontransgenic
bxs
s do not develop a significant tolerance of HBc/eAg-specific Th cells.
c mice born to and reared by HBeAg transgenic mothers (C) were
t epitope recognized by core-specific H-2d-restricted CD41 cells at an
splenocytes were harvested. Cultured splenocytes were restimulated
p129–140 and proliferative responses were evaluated by [3H]thymidine
te determinations and corrected for background radiation (Dcpm). The
. Note that the HBeAg transgenic mice (A) displayed a severe immune
the proliferation values of the BALB/c mice born to and reared by
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153HBe TOLERANCE INDUCTIONplasmid pGW-I1 and the humoral immune reactions were
monitored. As controls we used normal H-2sxb hybrids
and H-2sxb transgenic mice displaying a high-level
BeAg serum expression (data not shown). As depicted
n Fig. 4E the normal mice showed a vigorous antibody
esponse directed against the HBe protein. In contrast,
o HBeAg-specific antibodies could be detected in the
era of immunized transgenic H-2bxs mice (Fig. 4D) and
he HBeAg serum expression of these mice was not
ffected throughout the experiment (data not shown).
nterestingly, the specific humoral immune responses of
he nontransgenic H-2bxs mice born to and reared by
FIG. 4. H-2d and H-2bxs mice born to and reared by HBeAg-transgenic
females show a normal potential to synthesize HBeAg-specific anti-
bodies. HBeAg transgenic mice (A, D), normal isogenic controls (B, E),
and isogenic mice born to and reared by HBeAg-transgenic mothers (C,
F) of haplotypes H-2d (A–C) and H-2bxs (D–F) were genetically vacci-
ated with the HBeAg-encoding plasmid pGW-I1. Anti-HBe serum titers
ere monitored at months 0, 1, 2, 3, and 4 postimmunization. The
accinated normal H-2d and H-2bxs mice (B, E) showed a vigorous
HBe-specific antibody biosynthesis. In contrast, the immunized trans-
genic mice of both haplotypes did not exhibit significant anti-HBe
serum titers (A, D) and displayed stable HBeAg serum titers (data not
shown). Note that the anti-HBe serum titers observed in H-2d and H-2bxs
mice born to and reared by HBeAg-transgenic mothers (C, F) were
comparable to those of the normal isogenic controls (T test). The data
shown represent mean values and standard deviations of individual
anti-HBe determinations performed with the sera of 8 (A), 13 (B and C),
12 (D), and 20 (E and F) animals. The antibody titers were evaluated
using a reference serum of the Paul Ehrlich Institute and are presented
in Paul Ehrlich units (PE units) per milliliter of serum.BeAg-positive mothers (Fig. 4F) were similar to those of
he isogenic normal controls (T test).nduction of H-2d-restricted HBc/eAg-specific murine
CTL reactions depends on CD41 Th cells
To assess the extent to which the development of
H-2d-restricted CTL immune reactions toward HBc/eAg
ay depend on the help of CD41 Th cells, BALB/c mice
ere vaccinated with the HBeAg-encoding plasmid
GW-I1, previously shown to elicit significant CTL re-
ponses in H-2b mice (Reifenberg et al., 1998). One group
of immunized mice was depleted of CD41 cells by treat-
ment with CD4-specific monoclonal antibody, whereas
the other animals were injected with an immunologically
irrelevant control antibody. As depicted in Fig. 5A,
splenocytes prepared from the immunized controls
showed a vigorous lysis of specific target cells, indicat-
ing that the genetic vaccination protocol used was well
suited to elicit H-2d-restricted HBc/eAg-specific CTL re-
ponses. No specific lysis could be observed with the
plenocytes of those animals depleted of CD41 cells
(Fig. 5B), proving that induction of HBc/eAg-specific cy-
tolytic reactions in H-2d mice was strictly dependent on
he help of CD41 cells.
H-2d mice born to and reared by HBeAg-positive
others are not tolerant at the level
f HBc/eAg-specific CTLs
In a previous study (Reifenberg et al., 1998) we found
that mice of the haplotype H-2b born to HBeAg-positive
FIG. 5. HBc/eAg-specific CTL responses of H-2d mice depend on
CD41 Th cells. BALB/c mice (haplotype H-2d) were immunized with the
BeAg-encoding plasmid pGW-I1. After immunization animals of group
were treated with an immunologically irrelevant control antibody,
hereas mice of group B were depleted of CD41 T cells by treatment
ith a CD4-specific monoclonal antibody. Splenocytes were harvested
4 days postimmunization and restimulated with irradiated HBcAg-
xpressing P815/C transfectants. Cytolytic activity was determined us-
ng the HBcAg-expressing recombinant P815/C cell line and the non-
ransfected parental cell line P815. Note that CD41 cells are required
for the development of HBc/eAg-specific cytolytic reactions. The data
shown represent mean values plus standard deviations of chromium






154 MERKLE ET AL.mothers showed a normal reactivity of HBV core-specific
cytotoxic T cells. To verify this result in mice of the
haplotype H-2d, BALB/c mice derived from HBeAg-posi-
tive transgenic mothers were vaccinated with HBeAg-
encoding plasmid pGW-I1. As in the previous experi-
ments normal BALB/c mice and HBeAg transgenic ani-
mals (BALB/c–cex-1) were used as controls. Cultured
splenocytes of immunized mice of the three experimental
groups were restimulated with the stably transfected
HBcAg-expressing cell line P815/c and subjected to
chrom-release assays. As depicted in Fig. 6, the normal
BALB/c controls developed a vigorous immune response
as demonstrated by the efficient lysis of P815/C trans-
fectants (Fig. 6B) or of P815 targets pulsed with HBc/eAg
peptide p87–95 (Fig. 6D). Genetic vaccination has a spe-
cial potency to induce strong CTL immune responses.
Since we wanted to test whether perinatal HBeAg expo-
sure can induce immunologic tolerance of cytotoxic T
lymphocytes, we had to exclude the possibility that such
a tolerance once established was broken by DNA immu-
nization. Therefore, it was of pivotal importance to inves-
tigate the specific CTL reactivity of DNA-vaccinated
BALB/c–cex-1 transgenic mice. As shown in Fig. 6A, no
specific lysis was observed with the immunized trans-
genic mice, indicating that (i) constitutive HBeAg expres-
sion had induced tolerance at the CTL level and that (ii)
this tolerance was not broken by DNA immunization.
Since DNA vaccination could not break CTL tolerance in
transgenic animals, this type of immunization was well
suited to test the CTL reactivity of nontransgenic mice
originating from HBeAg-positive mothers. We found that
the splenocytes prepared from BALB/c mice born to
HBeAg-transgenic animals exhibited a lysis of HBcAg-
expressing P815/c cells (Fig. 6C) or p87–95-peptide-
pulsed P815 targets (Fig. 6E) comparable to that of
spleen cells of normal BALB/c controls (Figs. 6B and 6D;
T test), indicating that the potential contact with maternal
HBeAg at the perinatal developmental stage did not lead
to tolerance of specific H-2d-restricted CTLs.
DISCUSSION
Currently, the function of the secretory core gene prod-
ct HBeAg is still unknown. Along with other hypotheses
Lambert et al., 1993; Guidotti et al., 1996) it has also
been speculated that the HBe protein has the potential to
modulate the host’s immune response and thus to facil-
itate the development or maintenance of chronic infec-
tions. Two scenarios regarding how the HBe antigen may
lead to modulation of immunological reactivity can be
imagined.
On the one hand, it has been speculated that HBe
protein circulating in the vascular system of HBV-infected
individuals may directly promote chronicity of viral infec-
tion. This theory is supported by experimental studies
performed in the murine system, indicating that the se-
t
mcretory core gene product HBeAg preferentially elicits
immune responses of a Th2 phenotype, whereas the
particulate HBc antigen predominantly induces immuno-
logical reactions of a Th1 type (Milich et al., 1997, 1998).
Since the Th1 and Th2 cell subsets are cross-regulatory
(Hsieh et al., 1992; Seder et al., 1993) and since the major
unction of Th1 cells is to support inflammatory reactions,
FIG. 6. H-2d mice born to and reared by HBeAg-expressing females
are not tolerant at the level of HBc/eAg-specific CTLs. Seven HBeAg-
transgenic BALB/c–cex-1 mice (A), 10 normal BALB/c mice (B, D), and
11 nontransgenic BALB/c mice born to and reared by HBeAg-express-
ing cex-1 mothers (C, E) were immunized with the HBeAg-encoding
plasmid pGW-I1 between 40 and 60 days of age. Spleen cells were
prepared from the immunized mice 14 days postimmunization and
restimulated with irradiated HBcAg-expressing P815/C transfectants.
Specific cytolytic activity was assessed using either HBcAg-expressing
recombinant P815/C cells (A, B, C) or p87–95 peptide-pulsed P815
target cells (D, E). As negative controls the nonspecific lysis of P815
parental cells was determined in parallel. The data shown represent
mean values plus standard deviations of seven (A), nine (B, C), or four
(D, E) chromium release assays performed with individual or pooled
splenocytes. The transgenic mice showed tolerance of specific CTL
reactions (A). Note that the cytolytic activity of splenocytes prepared
from H-2d mice born to and reared by HBeAg-transgenic mothers (C, E)
as comparable to that of the normal isogenic controls (B, D).hese data suggested that the function of the HBe protein




































155HBe TOLERANCE INDUCTIONsary for viral clearance. The clinical observations that the
emergence of HBeAg-negative HBV mutants is fre-
quently associated with deterioration of liver disease
(Brunetto et al., 1991) and that babies infected with
HBeAg-negative HBV mutants develop an acute or ful-
minant rather than a persistent course of infection (Tera-
zawa et al., 1991) may be attributed to this potential
HBeAg action. In this context it is also important to
mention that it could be shown that endogenously syn-
thesized HBeAg but not HBcAg enters the major histo-
compatibility complex class II presentation pathway
(Diepolder et al., 1999). At present it is unclear whether
this mechanism may contribute to the immune tolerance
observed during chronic HBV infection.
On the other hand it has also been hypothesized that
the HBe protein may be transferred from HBV-infected
mothers to their babies where it may lead to HBV toler-
ance. This hypothesis is supported by the clinical finding
that persistently HBV-infected women who are HBeAg-
positive transmit the virus much more frequently to their
babies than chronic HBeAg-negative carriers (Okada et
al., 1976). Since prenatal antigen contact is especially
suited to induce immune tolerance, it was assumed that
the HBeAg can pass the murine placenta and operate as
a tolerogen in utero (Milich et al., 1990). However, a
multitude of arguments go against this hypothesis. First,
there are no clinical data that unambiguously show that
the HBe protein can in fact pass the placenta barrier.
Studies investigating whether the HBe protein may be
detectable in babies born to HBeAg-positive mothers are
generally hampered by the disadvantage that microleak-
age of maternal blood into the circulation of the newborn
cannot be excluded during tearing of the placenta at
birth. Furthermore, in some of those studies umbilical
cord sera were used for HBeAg determination, which
always bears the risk of contamination with maternal
blood (Arakawa et al., 1982; Biswas et al., 1989). More-
over, many of the HBeAg-positive cases that have been
reported were obviously due to infections that already
occurred in utero (Lee et al., 1989; Li et al., 1986). Second,
since the biosynthesis of the HBe protein is a reliable
clinical marker of viral replication, the virus titers of
HBeAg-positive carriers are usually several orders of
magnitude higher than those of HBeAg-negative carriers.
This fact alone can explain the higher rate of virus trans-
mission from HBeAg-positive mothers to their children.
Third, although the secretory core gene product cannot
operate as a perinatal inducer of immune tolerance in
birds, all avian hepadnaviruses known today encode
such a viral gene product.
There are only two studies in which a possible tolero-
genic effect of the HBeAg at the perinatal stage has been
tested experimentally (Milich et al., 1990; Reifenberg et
al., 1998). In the former report it could be shown that H-2slymphocytes obtained from nontransgenic mice born to
and reared by HBeAg-expressing transgenic mothers
exhibited a slightly impaired proliferative response to
HBV core gene products compared to normal controls.
The effect observed was weak, yet significant. Although
no evidence was presented in this study by which routes
and to what extent the HBeAg may have been transferred
from the transgenic mothers to the fetuses or newborns,
it was concluded that the HBe protein acts as a tolero-
gen in utero. In a previous study (Reifenberg et al., 1998)
we could demonstrate that the murine placenta is an
efficient barrier for the HBeAg and that mice born to and
reared by HBeAg transgenic mothers do not develop a
tolerance of H-2b-restricted CTLs. In the present study
e tried to clarify these contradictory results.
Possible routes by which the HBeAg may be trans-
erred from HBeAg-positive mothers to their babies at the
ostnatal stage include the lactogenic and the renal
outes. To investigate the relevance of these transfer
echanisms we determined the concentrations of
BeAg in milk and urine of transgenic mice. We found
hat lactating HBeAg-positive mice harbored small
mounts of the viral protein in milk and excreted minor
uantities of the antigen in urine. Since the possibility
an be excluded that the HBe protein is resorbed actively
y the renal tubular epithelial cells, the latter finding can
e attributed only to inefficient glomerular filtration. This
esult stresses our previous hypothesis that biological
embranes represent an efficient barrier for the secre-
ory core gene product (Reifenberg et al., 1998). The
BeAg positivity observed with the milk of cex-1 trans-
enic mice may be due to secretion of circulating HBeAg
ut can also result from ectopic transgene expression.
owever, since in a recent clinical study the HBe protein
ould also be detected in the colostrum of HBeAg-posi-
ive carrier women (Yang et al., 1994), we favor the former
ypothesis. Summarizing, we could demonstrate that in
he model of cex transgenic mice transplacental HBeAg
ransfer is inefficient, if occurring at all (Reifenberg et al.,
998), whereas the HBeAg could be detected in trans-
enic milk and urine, even if at low and minor concen-
rations, respectively. Since it is well established that
ice can be tolerized by oral application of proteins
Peng et al., 1990, 1995; Moreau and Gaboriau-Routhiau,
996), the role of maternal lactogenic HBeAg secretion
or the pathogenesis of chronic hepatitis B in suckling
abies should be further investigated.
In an attempt to analyze the extent to which transpla-
ental, lactogenic, and renal HBeAg transfer may act
ynergistically in inducing murine immune tolerance, we
nvestigated the specific immunological reactivity of non-
ransgenic H-2d mice born to and reared by HBeAg-
positive transgenic females. The H-2d haplotype is well
suited to such experiments since (i) it allows for the
efficient induction of HBc/eAg-specific Th cell and CTL












156 MERKLE ET AL.toward HBc/eAg can be tolerized as shown by the spe-
cific immunological nonresponsiveness of BALB/c
HBeAg-transgenic mice. We could show that within the
H-2d haplotype system HBeAg-specific CTL reactions
induced by genetic vaccination depend on the help of
CD41 Th cells. These data are in line with the hypothesis
that the interaction of antigen-specific T helper cells,
antigen-loaded dendritic cells, and T killer cells is nec-
essary for the development of cytotoxic immune re-
sponses (Bennett et al., 1998; Ridge et al., 1998; Schoen-
erger et al., 1998). We found no evidence that nontrans-
genic H-2d animals born to and reared by HBeAg-
positive mothers develop a tolerance of CD41 Th cells
toward the core gene products. In line with this finding
the HBeAg-specific humoral and CTL reactions of these
animals were comparable to those of normal BALB/c
controls. Furthermore, we could show that the anti-HBe
responses of H-2bxs hybrid mice potentially exposed to
BeAg at the perinatal stage were comparable to those
f normal isogenic animals.
In summary, our murine experimental data do not
upport the hypothesis that HBe protein expressed by
BV carrier women induces immunologic tolerance in
heir offspring. Hence, the present work supports our
revious study using mice of the H-2b haplotype (Reifen-
berg et al., 1998) but challenges the data of Milich and
co-workers who used H-2s mice (Milich et al., 1990). In
his context it should be noted that the immunologic
olerance observed in the H-2s mice born to and reared
by HBeAg-transgenic mice was rather weak. It may be
speculated that this effect was due to a high-level ec-
topic HBeAg biosynthesis of kidneys, mammary glands,
or placenta of the transgenic mice used, which may lead
to transfer of abnormal quantities of HBeAg to the non-
transgenic offspring. Alternatively, the H-2s-restricted
HBeAg-specific Th cell responses evaluated in this study
may be especially susceptible to tolerogenic effects.
However, the latter hypothesis is incompatible with our
finding that H-2bxs hybrid mice born to and reared by
HBeAg transgenic mice did not display an impaired hu-
moral immune response directed against the secretory
core gene product.
MATERIALS AND METHODS
Transgenic mice and breeding schemes
Production and characterization of cex-1 transgenic
mice coexpressing the HBV core and X genes (ayw
subtype) under transcriptional regulation of the hepad-
naviral promoters have been reported previously (Reif-
enberg et al., 1997). In previous works (Reifenberg et al.,
1997, 1998) strain cex-1 had been designated cexL. The
congenic transgenic variant BALB/c–cex-1 was obtained
by crossing cex-1 transgenic mice to the BALB/c inbredstrain for 10 generations. Transgenic animals were rou-
tinely bred by mating hemizygous BALB/c–cex-1 trans-
genic males with nontransgenic BALB/c females. Pater-
nal inheritance of the cex-1 transgene results in good
expression of HBeAg in the serum and HBcAg in the liver
parenchyma.
Generation and characterization of transgenic line B6-
ce-1 have been described recently (Reifenberg et al.,
1999; Merkle et al., 2000). Briefly, the DNA construct
introduced into ce-1 mice was derived from the construct
used for the establishment of cex-1 transgenic mice but
the translational start codon of the HBV X gene had been
deleted. Transgenic B6-ce-1 mice are coisogenic to the
B6 inbred strain. Such animals express large amounts of
HBcAg in liver, kidneys, and pancreas and display a
high-level expression of HBeAg in the serum. Impor-
tantly, transgenic variant B6-ce-1 does not exhibit any
genomic imprinting effect.
DNA sequence analyses of the HBV core promoter
region harbored by cex-1 and ce-1 transgenic mice re-
vealed that both transgenic lines lack HBV nucleotide
2431 (nucleotide positions are relative to the HBc-ATG
with the A being nucleotide 1) located in the regulatory
region upstream of the X-ORF.
To investigate whether a potential perinatal HBeAg
exposure may tolerize H-2d BALB/c mice, hemizygous
BALB/c–cex-1 transgenic females were mated with non-
transgenic male BALB/c mice and the nontransgenic
descendants were used for immunological analyses.
Transgenic littermates resulting from this mating had to
be discarded, since the maternally transmitted cex-1
transgene is barely expressed due to a genomic imprint-
ing effect. Instead, BALB/c–cex-1 transgenic mice result-
ing from paternal transgene inheritance were used as
HBeAg-expressing positive controls. As negative con-
trols we used normal BALB/c mice.
To evaluate whether the H-2s-restricted HBV-specific
humoral immune responses toward the HBeAg may be
impaired by potential HBeAg exposure at the perinatal
stage, hemizygous HBeAg-transgenic females of strain
B6-ce-1 were mated with B10.S males and the resulting
nontransgenic descendants (haplotype H-2bxs) were sub-
ected to immunological tests. The transgenic littermates
ere used as HBeAg-transgenic positive controls. As
BeAg-negative controls we used B6 3 B10.S (H-2bxs)
hybrid mice.
All mice used in the present study were maintained at
the Laboratory Animal Research Unit of the University of
Ulm under SPF conditions. Transgenic mice were iden-
tified from their nontransgenic littermates by PCR ampli-
fication of transgene-specific sequences from chromo-
somal DNA using primer combinations 59 GAG ATG GGG
TTA CTC TCT 39 and 59 CCT TGT AAG TTG GCG AGA 39
or alternatively 59 GGA GCT ACT GTG GAG TTA CTC 39




























































157HBe TOLERANCE INDUCTIONHBeAg detection in murine serum, milk, and urine
samples
For quantitative determination of HBeAg, 30 ml of the
ody fluids mentioned was diluted with 170 ml fetal calf
erum and subjected to the IMX HBe assay (Abbott
aboratories, Wiesbaden, Germany). The test was quan-
itated with an HBeAg reference antigen of the Paul
hrlich Institut (Paul Ehrlich Institut, Langen, Germany)
s described previously (Reifenberg et al., 1998; Merkle
t al., 2000). The data are presented in nanograms of
BeAg per milliliter.
etermination of serum anti-HBe levels
HBeAg-specific antibodies were detected using the
MX anti-HBe assay (Abbott). The test was standardized
sing a reference serum of the Paul Ehrlich Institut as
escribed previously (Kuhrober et al., 1996). The data are
resented in Paul Ehrlich units (PE Units) per milliliter.
eptides
Peptides p85–100 (VVSYVNTNMGLKFRQL), p129–140
PPAYRPPNAPIL), and p87–95 (SYVNTNMGL) were syn-
hesized in an Applied Biosystems peptide synthesizer
odel 431A (Foster City, CA) and purified by reverse-
hase HPLC.
mmunizations and in vivo depletion of CD41 cells
All genetic vaccinations were performed using the
BeAg-encoding plasmid pGW-I1 (Reifenberg et al.,
998). Plasmid DNA was isolated from transformed
scherichia coli cultures using the Qiagen plasmid ex-
raction kit (Qiagen, Hilden, FRG). For immunizations 50
ml plasmid solution (1 mg/ml) was injected into the re-
enerating musculus tibialis anterior 5 days after pre-
reatment with cardiotoxin (Latoxan, Rosans, France;
avis et al., 1993a,b).
For peptide immunizations 100 mg of peptide p85–100
was dissolved in distilled water, emulsified with Freund’s
complete adjuvant (Sigma, Deisenhofen, FRG), and in-
jected at the base of the tail.
For in vivo depletion of CD41 cells, immunized animals
ere treated with a monoclonal CD4-specific antibody har-
ested from hybridoma clone YTS 191 (ATCC, Manassas,
A). The control animals received rat IgG (ChromPure, Di-
nova, Hamburg, FRG). Successful depletion was con-
rolled for by FACS analysis of peripheral blood leukocytes
FACScan, Becton Dickinson, Heidelberg, FRG).
cell proliferation assay
Peptide p85–100-treated mice were sacrificed at day 12
ostimmunization and splenocytes were harvested. Spleen
ells were adjusted to a density of 5 3 106 per milliliter and
ultured (37°C, 10% CO2) in RPMI medium supplemented
ith 10% v/v FCS, 1% w/v glutamine, 5 3 1025 mM mercap-toethanol, and antibiotics in round-bottom 96-well culture
plates. The primed cells were restimulated for 48 h with
various concentrations of peptide p85–100 or p129–140.
After addition of [3H]thymidine (1 mCi, Amersham, Arlington
Heights, IL) to the wells and an additional 16-h culture
period the cells were harvested to glass-fiber filters using a
96 microplate harvester (Wallac, Pharmacia). [3H]Thymidine
ptake was determined using a liquid scintillation counter
Wallac beta-scintillation counter). The proliferation levels of
ndividual animals were assessed in triplicate and cor-
ected for background radiation in the absence of antigen
Dcpm).
In some experiments splenocytes were depleted of
D41 cells by immunomagnetic-negative selection prior
to peptide restimulation. Therefore, the splenocytes were
adjusted to a density of 1 3 108/ml and incubated (20
min, 4°C) with CD4-coated magnetic microbeads. Deple-
tion was controlled by immunofluorescence staining us-
ing a PE-conjugated anti-CD4 antibody and a FITC-con-
jugated anti-CD3 antibody. The residual contamination of
depleted cell suspensions was less than 1%.
Cytotoxicity assay
The CTL assay was performed as described previ-
ously (Kuhrober et al., 1997). Briefly, spleen cells from
DNA-immunized mice were cultured in a-MEM supple-
ented with 10 mM HEPES, 5 3 1025 M 2-mercaptoetha-
ol, antibiotics, and 10% v/v fetal calf serum. For restimu-
ation, the syngeneic core protein expressing recombi-
ant cell line P815/C was used (Kuhrober et al., 1997). A
otal of 3 3 107 responder cells were cocultured with
.5 3 106 irradiated (20,000 rad) stimulator cells in 10 ml
medium in upright 25-cm2 tissue culture flasks in a hu-
midified atmosphere (7% CO2) at 37°C. Cytotoxic effector
populations were harvested after day 4 of coculture and
washed twice. Serial dilutions of effector cells were in-
cubated with 2 3 103 51Cr-labeled P815/C transfectants
r p87–95 peptide pulsed target cells in round-bottom
icrotiter plates for 4 h. As a control for the specificity of
he cytolytic reaction the lysis of 51Cr-labeled P815 pa-
ental cells was determined in parallel. Cytolysis of la-
eled target cells was evaluated in triplicate determina-
ions. The percentage specific lysis was calculated as
(experimental release 2 spontaneous release)/(total re-
ease 2 spontaneous release)] 3 100. In all experiments
he spontaneously released 51Cr was always less than
0% of the total label.
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